Ian is the editor and a director of Proactive Investors. He oversees all editorial output and is also heavily involved with business development. He moved to Proactive from the Daily Mail, where he was City News Editor and Investment Editor and brings with him a wealth of experience in business and finance. At the Mail he directed the coverage of some of the biggest stories ever to emerge from the City as the credit crunch and banking crisis felled some of the nation's best known financial institutions. In his 20 years as a business reporter and editor Ian has worked for Dow Jones, writing stories for the international news wire and the Wall Street Journal. He also led the London company coverage for AFX News, now part of Reuters.
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara
Eighteen of the top 20 big pharmaceutical companies now provide early access to their drugs
The first data should start coming through next month
Unlike most penem drugs, Iterum’s sulopenem can be taken orally, which is why analysts think it has the potential to become a blockbuster antibiotic drug
A total of 17,000 people with type-2 diabetes took part in the study
In clinical trials, 75% of the people taking the drug responded to it. In 30% of cases, Lumoxiti had a “complete durable” effect
Takhzyro is the first monoclonal antibody treatment for hereditary angioedema, a rare genetic condition
The innovative dressings help prevent and treat infection and accelerate the healing
Two companies, three wells
Drilling down into the world of E&P as we keep tabs of on the gushers and dusters
A look at some early analyst views in the City
The bookmakers have been put under the microscope, while Shell has been downgraded.